| |
|
|
|
|
|
 |
| |
|
ºñ½ºÆ®·ÑÁ¤(µð¿¡Ä¥½ºÆ¿º£½ºÆ®·Ñ)(¼öÃâ¿ë) BISTROL TABS.[Diethylstilbestrol]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
644301400[A12941291]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2014.03.01)(ÇöÀç¾à°¡)
\60 ¿ø/1Á¤(2014.02.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»öÀÇ ¿øÇü Á¤Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
100TABS |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 1¹Ð¸®±×·¥ |
100 Á¤ |
º´ |
8806443014008 |
8806443014015 |
|
|
| ÁÖ¼ººÐÄÚµå |
364701ATB
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
- Àü¸³¼±¾Ï
- Æó°æ ÈÄÀÇ ÀüÀ̼º À¯¹æ¾Ï
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:364701ATB ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
- Àü¸³¼±¾Ï : µð¿¡Ä¥½ºÆ¿º£½ºÆ®·Ñ·Î¼ 1ÀÏ 1-3mgÀ» °æ±¸Åõ¿©ÇÑ´Ù. Á¡Â÷ÀûÀ¸·Î 1ÀÏ 1mg±îÁö °¨·®ÇÑ´Ù.
- Æó°æ ÈÄÀÇ ÀüÀ̼º À¯¹æ¾Ï : ÀÌ ¾àÀ¸·Î¼ 1ÀÏ 10-15mgÀ» Åõ¿©ÇÑ´Ù.
|
| ±Ý±â |
- ¿¡½ºÆ®·Î°Õ ÀÇÁ¸¼º Á¾¾ç(¿¹ :
À¯¹æ¾Ï, Àڱ󻸷¾Ï) ¶Ç´Â ÀǽÉÀÌ µÇ´Â ȯÀÚ ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ(Á¾¾çÀ» ¾ÇÈ ¶Ç´Â Çö¼ºÈ½Ãų ¼ö ÀÖ´Ù)
ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ ¹× Æó°æ ÀÌÀüÀÇ ¿©¼º
Áø´ÜÇÏÁö ¾ÊÀº ºñÁ¤»óÀûÀÎ »ý½Ä±â ÃâÇ÷ ȯÀÚ
½ÉÇ÷°ü, ³úÇ÷°ü ¶Ç´Â °ü»óµ¿¸Æ Áúȯ ȯÀÚ
Ç÷Àü¼º Á¤¸Æ¿° ¶Ç´Â Ç÷Àü»öÀüÁõ ȯÀÚ(Ç÷ÀüÇü¼º °æÇâÀÌ Áõ°¡µÉ ¼ö ÀÖ´Ù)
¿¡½ºÆ®·Î°ÕÀÇ »ç¿ëÀ¸·Î ÀÎÇÑ Ç÷Àü¼º Á¤¸Æ¿° ¶Ç´Â Ç÷Àü»öÀüÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
ÀÌ ¾à¿¡ °ú¹ÎÁõ ȯÀÚ
¼Ò¾Æ
Àڱ󻸷Áõ½ÄÁõ ȯÀÚ
ÀڱñÙÁ¾ ȯÀÚ
Àӽů÷ÁøÀÇ º´·ÂÀÌ Àִ ȯÀÚ
Æ÷¸£ÇǸ°Áõ ȯÀÚ
Áߵ ¶Ç´Â ÁßÁõ °íÇ÷¾Ð ȯÀÚ
ÁßÁõ ¶Ç´Â Ȱµ¿¼º °£Áúȯ ȯÀÚ
°íÁö´Ü¹éÇ÷Áõ ȯÀÚ |
| ½ÅÁßÅõ¿© |
- ¿ì¿ïÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ(¿ì¿ïÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù)
- ÀӽŠÁß È²´Þ ¹× ´ãÁó¿ïü¼º Ȳ´ÞÀÇ º´·ÂÀÌ Àִ ȯÀÚ
- °£±â´É Àå¾Ö ȯÀÚ
- °£Áú, ÆíµÎÅë, ½É ¹× ½ÅÁúȯ ȯÀÚ
- ½Å±â´É Àå¾Ö ȯÀÚ
- ´Ù°ø¼º °ñÁúȯ ȯÀÚ
- ¼öÀ¯ºÎ
- ½ÉºÎÀü ȯÀÚ
- °íÇ÷¾Ð ȯÀÚ
- ´ç´¢º´ ȯÀÚ(³»´ç·ÂÀÌ ¾Ç鵃 ¼ö ÀÖ´Ù)
- ´ã¼®Áõ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
- ºñ´¢»ý½Ä±â°è
- ¿©¼º :
ÆÄ±«¼ºÃâÇ÷, Á¡ÀûÃâÇ÷, ¿ù°æ·® º¯È, ¿ù°æºÒ¼ø, ¿ù°æÀü¾ç ÁõÈıº, Ä¡·á±â°£°ú Ä¡·áÈÄÀÇ ¹«¿ù°æ, ÀڱñÙÁ¾ Å©±âÀÇ Áõ´ë, Áúĵð´ÙÁõ, ÀڱðæºÎ¹Ì¶õ ¹× °æºÎºÐºñ Á¤µµÀÇ º¯È, ¹æ±¤¿°¾ç ÁõÈıº, Àڱ󻸷ÁõÀÇ ¾ÇÈ ¶Ç´Â Àç¹ß, Àڱ󻸷Áõ½ÄÁõ, Àڱ󻸷 Á¾¾ç°ú ¾ÏÁ¾ÀÇ À§Ç輺 Áõ°¡ µî
- ³²¼º :
¿©¼ºÇü À¯¹æ, °íȯÀÇ À§Ãà, ¹ß±âºÒ´É
À¯¹æ : À¯¹æÅë, À¯¹æ±ä¸¸°¨ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¼Òȱâ°è : ±¸¿ª, ±¸Åä, º¹ºÎ°æ·Ã, º¹ºÎÆØ¸¸, ´ãÁó¿ïü¼º Ȳ´Þ, ½Ä¿åºÎÁø, ´ã¼®Áõ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ÇǺΠ: ¾à¹°Åõ¿© ÁßÁö½Ã Áö¼ÓµÇ´Â °£¹Ý ¹× ÈæÇÇÁõ, ´ÙÇü¼º È«¹Ý, °áÀý¼º È«¹Ý, ÃâÇ÷¼º ¹ßÁø, µÎÇǼսÇ, Á¶¸ðÁõ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
´« : °¢¸· ¸¸°îÀÇ ½ÉÈ, ÄÜÅÃÆ®·»Áî¿¡ ´ëÇÑ °¨¼ö¼º ÀÌ»ó µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ÁßÃ߽Űæ°è : µÎÅë, ÆíµÎÅë, ¾îÁö·¯¿ò, Á¤½Å¿ì¿ïÁõ, ¹«µµº´ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
¼øÈ¯±â°è : °íÇ÷¾Ð, Á¤¸Æ Ç÷ÀüÁõ, Ç÷Àü»öÀüÁõ, ³úÇ÷ÀüÁõ, °ü»óµ¿¸Æ Ç÷ÀüÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
±âŸ : üÁßÀÇ Áõ°¡ ¶Ç´Â °¨¼Ò, ³»´ç·Â °¨¼Ò, Æ÷¸£ÇǸ°ÁõÀÇ ¾ÇÈ, ÈäÅë, ¼º¿åÀÇ º¯È µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
³Æ÷È£¸£¸ó(ÁÖ·Î °áÇÕÇü¿¡½ºÆ®·Î°Õ, ÇÕ¼º ¿¡½ºÆ®·Î°Õ)Àº ³»´ç·ÂÀÇ º¯È¸¦ ÀÏÀ¸ÄÑ Ç÷´ç»ó½ÂÀÛ¿ëÀ» ³ªÅ¸³»¹Ç·Î Ç÷´ç°ÇÏÁ¦¿Í º´¿ëÅõ¿©½Ã Ç÷´ç°ÇÏÀÛ¿ëÀÌ °¨¼ÒµÉ ¼ö ÀÖ´Ù. ±×·¯¹Ç·Î ´ç´¢º´ ȯÀÚ¿¡ ÀÌ ¾à Åõ¿©½Ã Ç÷´ç°ÇÏÁ¦ÀÇ ¿ë·®À» Á¶ÀýÇÏ´Â µî ÁÖÀÇÇÑ´Ù. |
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Xµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
ÀÓ»êºÎ ¶Ç´Â ÀӽŰèȹÁß º¹¿ë±ÝÁö |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Diethylstilbestrol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
|
| Pharmacology |
Diethylstilbestrol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Diethylstilbestrol is a synthetic estrogen that was developed to supplement a woman's natural estrogen production. In 1971, the Food and Drug Administration (FDA) issued a Drug Bulletin advising physicians to stop prescribing DES to pregnant women because it was linked to a rare vaginal cancer in female offspring.
|
| Metabolism |
Diethylstilbestrol¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Catechol O-methyltransferase (COMT)Cytochrome P450 19 (Aromatase)Cytochrome P450 2A6 (CYP2A6)
|
| Protein Binding |
Diethylstilbestrol¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Diethylstilbestrol¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Diethylstilbestrol¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
DiethylstilbestrolÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : À§Àå°ü¿¡¼ Àß Èí¼ö, Àå°£¼øÈ¯
- ºÐÆ÷ : ÅÂ¹Ý Åë°ú, À¯ÁóºÐºñ
- ´ë»ç : °£¿¡¼ ¼¼È÷ ºñȰ¼º ¹°Áú·Î ´ë»ç
- ¼Ò½Ç : Æ÷ÇÕü·Î ¼Òº¯°ú ´ãÁóÀ¸·Î ¹è¼³
|
| Biotransformation |
Diethylstilbestrol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic.
|
| Toxicity |
Diethylstilbestrol¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.
|
| Drug Interactions |
Diethylstilbestrol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Amobarbital The enzyme inducer decreases the effect of hormonesAprobarbital The enzyme inducer decreases the effect of hormonesButabarbital The enzyme inducer decreases the effect of hormonesButalbital The enzyme inducer decreases the effect of hormonesButethal The enzyme inducer decreases the effect of hormonesEthotoin The enzyme inducer decreases the effect of hormonesFosphenytoin The enzyme inducer decreases the effect of hormonesGriseofulvin The enzyme inducer decreases the effect of hormonesHeptabarbital The enzyme inducer decreases the effect of hormonesHexobarbital The enzyme inducer decreases the effect of hormonesMephenytoin The enzyme inducer decreases the effect of hormonesMethohexital The enzyme inducer decreases the effect of hormonesMethylphenobarbital The enzyme inducer decreases the effect of hormonesPentobarbital The enzyme inducer decreases the effect of hormonesPhenobarbital The enzyme inducer decreases the effect of hormonesPhenytoin The enzyme inducer decreases the effect of hormonesPrednisolone The estrogenic agent increases the effect of corticosteroidPrednisone The estrogenic agent increases the effect of corticosteroidPrimidone The enzyme inducer decreases the effect of hormonesRaloxifene Association not recommendedSecobarbital The enzyme inducer decreases the effect of hormonesTalbutal The enzyme inducer decreases the effect of hormonesUrsodeoxycholic acid Estrogens decreases the effect of ursodiol
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Diethylstilbestrol¿¡ ´ëÇÑ Food Interaction Á¤º¸ Not Available
|
| Drug Target |
[Drug Target]
|
| Description |
Diethylstilbestrol¿¡ ´ëÇÑ Description Á¤º¸ A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed)
|
| Dosage Form |
Diethylstilbestrol¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Tablet Oral
|
| Drug Category |
Diethylstilbestrol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antineoplastic Agents, HormonalCarcinogensEstrogens, Non-Steroidal
|
| Smiles String Canonical |
Diethylstilbestrol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CCC(C1=CC=C(O)C=C1)=C(CC)C1=CC=C(O)C=C1
|
| Smiles String Isomeric |
Diethylstilbestrol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC\C(C1=CC=C(O)C=C1)=C(\CC)C1=CC=C(O)C=C1
|
| InChI Identifier |
Diethylstilbestrol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3
|
| Chemical IUPAC Name |
Diethylstilbestrol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 4-[4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol
|
| Drug-Induced Toxicity Related Proteins |
DIETHYLSTILBESTROL (DES) ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Peroxidase Drug:diethylstilbestrol (DES) Toxicity:unscheduled DNA synthesis (UDS). [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-11-03
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|